FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3011441619> ?p ?o ?g. }

• W3011441619 endingPage "869" @default.
• W3011441619 startingPage "854" @default.
• W3011441619 abstract "Abstract Aims We sought to identify the most effective antidysrhythmic drug for pharmacologic cardioversion of recent-onset atrial fibrillation (AF). Methods and results We searched MEDLINE, Embase, and Web of Science from inception to March 2019, limited to human subjects and English language. We also searched for unpublished data. We limited studies to randomized controlled trials that enrolled adult patients with AF ≤ 48 h and compared antidysrhythmic agents, placebo, or control. We determined these outcomes prior to data extraction: (i) rate of conversion to sinus rhythm within 24 h, (ii) time to cardioversion to sinus rhythm, (iii) rate of significant adverse events, and (iv) rate of thromboembolism within 30 days. We extracted data according to PRISMA-NMA and appraised selected trials using the Cochrane review handbook. The systematic review initially identified 640 studies; 30 met inclusion criteria. Twenty-one trials that randomized 2785 patients provided efficacy data for the conversion rate outcome. Bayesian network meta-analysis using a random-effects model demonstrated that ranolazine + amiodarone intravenous (IV) [odds ratio (OR) 39.8, 95% credible interval (CrI) 8.3–203.1], vernakalant (OR 22.9, 95% CrI 3.7–146.3), flecainide (OR 16.9, 95% CrI 4.1–73.3), amiodarone oral (OR 10.2, 95% CrI 3.1–36.0), ibutilide (OR 7.9, 95% CrI 1.2–52.5), amiodarone IV (OR 5.4, 95% CrI 2.1–14.6), and propafenone (OR 4.1, 95% CrI 1.7–10.5) were associated with significantly increased likelihood of conversion within 24 h when compared to placebo/control. Overall quality was low, and the network exhibited inconsistency. Probabilistic analysis ranked vernakalant and flecainide high and propafenone and amiodarone IV low. Conclusion For pharmacologic cardioversion of recent-onset AF within 24 h, there is insufficient evidence to determine which treatment is superior. Vernakalant and flecainide may be relatively more efficacious agents. Propafenone and IV amiodarone may be relatively less efficacious. Further high-quality study is necessary." @default.
• W3011441619 created "2020-03-23" @default.
• W3011441619 creator A5031966355 @default.
• W3011441619 creator A5036298172 @default.
• W3011441619 creator A5053683108 @default.
• W3011441619 creator A5054258032 @default.
• W3011441619 creator A5058104390 @default.
• W3011441619 creator A5088652420 @default.
• W3011441619 date "2020-03-16" @default.
• W3011441619 modified "2023-09-25" @default.
• W3011441619 title "Pharmacologic cardioversion of recent-onset atrial fibrillation: a systematic review and network meta-analysis" @default.
• W3011441619 cites W1517555081 @default.
• W3011441619 cites W1617328014 @default.
• W3011441619 cites W1964087992 @default.
• W3011441619 cites W1970252226 @default.
• W3011441619 cites W1989832493 @default.
• W3011441619 cites W1995602139 @default.
• W3011441619 cites W1998994470 @default.
• W3011441619 cites W1999727365 @default.
• W3011441619 cites W2004953997 @default.
• W3011441619 cites W2022539238 @default.
• W3011441619 cites W2031651171 @default.
• W3011441619 cites W2032383957 @default.
• W3011441619 cites W2033630717 @default.
• W3011441619 cites W2035710068 @default.
• W3011441619 cites W2041524645 @default.
• W3011441619 cites W2045039495 @default.
• W3011441619 cites W2051923490 @default.
• W3011441619 cites W2053132213 @default.
• W3011441619 cites W2054167248 @default.
• W3011441619 cites W2058611168 @default.
• W3011441619 cites W2059662721 @default.
• W3011441619 cites W2062279066 @default.
• W3011441619 cites W2072512746 @default.
• W3011441619 cites W2075337473 @default.
• W3011441619 cites W2079438910 @default.
• W3011441619 cites W2086499634 @default.
• W3011441619 cites W2098995101 @default.
• W3011441619 cites W2104750871 @default.
• W3011441619 cites W2109391487 @default.
• W3011441619 cites W2121240867 @default.
• W3011441619 cites W2126557119 @default.
• W3011441619 cites W2135009225 @default.
• W3011441619 cites W2142056543 @default.
• W3011441619 cites W2143627466 @default.
• W3011441619 cites W2152235423 @default.
• W3011441619 cites W2159975225 @default.
• W3011441619 cites W2162833322 @default.
• W3011441619 cites W2163781421 @default.
• W3011441619 cites W2164238702 @default.
• W3011441619 cites W2169263905 @default.
• W3011441619 cites W2170350621 @default.
• W3011441619 cites W2286228684 @default.
• W3011441619 cites W2320656453 @default.
• W3011441619 cites W2582526402 @default.
• W3011441619 cites W2586637755 @default.
• W3011441619 cites W2766186002 @default.
• W3011441619 cites W2778549000 @default.
• W3011441619 cites W2793138906 @default.
• W3011441619 cites W2884040064 @default.
• W3011441619 cites W2897709694 @default.
• W3011441619 cites W2913705661 @default.
• W3011441619 cites W2914623427 @default.
• W3011441619 cites W2915092822 @default.
• W3011441619 cites W2921522488 @default.
• W3011441619 cites W2923122590 @default.
• W3011441619 cites W4205645630 @default.
• W3011441619 cites W4239429542 @default.
• W3011441619 cites W4240380219 @default.
• W3011441619 doi "https://doi.org/10.1093/europace/euaa024" @default.
• W3011441619 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32176779" @default.
• W3011441619 hasPublicationYear "2020" @default.
• W3011441619 type Work @default.
• W3011441619 sameAs 3011441619 @default.
• W3011441619 citedByCount "8" @default.
• W3011441619 countsByYear W30114416192020 @default.
• W3011441619 countsByYear W30114416192021 @default.
• W3011441619 countsByYear W30114416192022 @default.
• W3011441619 countsByYear W30114416192023 @default.
• W3011441619 crossrefType "journal-article" @default.
• W3011441619 hasAuthorship W3011441619A5031966355 @default.
• W3011441619 hasAuthorship W3011441619A5036298172 @default.
• W3011441619 hasAuthorship W3011441619A5053683108 @default.
• W3011441619 hasAuthorship W3011441619A5054258032 @default.
• W3011441619 hasAuthorship W3011441619A5058104390 @default.
• W3011441619 hasAuthorship W3011441619A5088652420 @default.
• W3011441619 hasBestOaLocation W30114416191 @default.
• W3011441619 hasConcept C126322002 @default.
• W3011441619 hasConcept C142724271 @default.
• W3011441619 hasConcept C156957248 @default.
• W3011441619 hasConcept C164705383 @default.
• W3011441619 hasConcept C168563851 @default.
• W3011441619 hasConcept C204787440 @default.
• W3011441619 hasConcept C27081682 @default.
• W3011441619 hasConcept C2775914520 @default.
• W3011441619 hasConcept C2777008848 @default.
• W3011441619 hasConcept C2777289489 @default.
• W3011441619 hasConcept C2778094803 @default.

• next